IBTA advisor published in New Scientist magazine

By IBTA News

[9 January 2015]   Dr Stuart Farrimond, the IBTA’s digital technology advisor, has written an article for New Scientist magazine titled “Radical therapies that could beat my brain tumour” (New Scientist, Issue No. 3003, 10 January 2015). As a former practising medical doctor, and a brain tumour survivor, Stu offers an insightful look at four of the most promising brain tumour treatments currently in development.

You can read his article in full here.

The IBTA Exhibits at SNO 2014 in Miami

By IBTA News

[30 November 2014]   The Society for Neuro-Oncology 2014 Annual Meeting (SNO 2014) was held in Miami, Florida on 13-16 November 2014. Over 1,900 delegates from 43 countries attended the conference, confirming it as the largest and most important neuro-oncology-specific event of the year.

A major highlight of the conference was the presentation by Dr Roger Stupp of the interim results from Novocure’s phase III clinical trial in newly diagnosed GBM (EF-14). The overall survival (OS) data was very positive and has resulted in early termination of the trial due to success. Other highlights included presentations on: Celldex Therapeutics’ immunotherapy treatment, rindopepimut; the use of bevacizumab (Avastin) and lomustine in recurrent GBM; the addition of PCV (procarbazine, CCNU and vincristine) to radiotherapy for the treatment of low grade gliomas; and the genomic characterisation of diffuse low grade gliomas. All of these studies may eventually lead to changes in clinical practice.

The IBTA was recognised with a SNO Public Service Award presented in absentia to the former chair, Denis Strangman (Australia). Our full report from the conference can be downloaded here.

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.